|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FABP5 overexpression is frequent in PCa, but seems to be restricted to TMPRESS2:ERG fusion-negative tumors and is associated with SPOP and FOXA1 mutations.
|
30701334 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results from the present study indicated that SPOP expression was significantly downregulated in human epithelial ovarian cancer and was associated with the FIGO stage and the histopathologic grading of the tumor.
|
31819473 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that NANOG is degraded by SPOP, a frequently mutated tumor suppressor of PCa.
|
30595535 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, SPOP acts as a tumor suppressor in DLBCL.
|
31776466 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, the tumor suppressor SPOP promotes DAXX degradation in phase-separated droplets.
|
31350900 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutations in the gene encoding the tumor suppressor speckle-type POZ protein (SPOP), which is a E3 ubiquitin ligase, are a critical feature of PCa.
|
30955223 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SPOP or FOXA1 alterations (mutations or expression loss) were significantly more common in GG5, while isolated ERG overexpression was more common in GG1 tumors (P = 0.042).
|
31090082 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa.
|
30595538 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, SPOP acts as a tumor suppressor via destabilizing downstream oncoproteins in many malignancies, especially in prostate cancer.
|
29128526 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments.
|
30244836 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To identify molecular mediators of the tumor suppressive function of SPOP, we performed a yeast two-hybrid screen in a HeLa cDNA library using the full-length SPOP as bait.
|
29996942 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, our results help to elucidate the tumor suppressor role of SPOP in the prostate cancer setting by negatively controlling BET proteins stability.
|
29108467 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SPOP mutations were investigated from tumor DNA by Sanger sequencing.
|
28699202 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function.
|
28414305 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, our study not only underlines an oncogenic role of EglN2 in prostate cancer, but also highlights SPOP as a tumor suppressor to down-regulate EglN2 in prostate cancer.
|
28089830 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Detected alterations included AR amplifications in 22 (64.7%) samples, SPOP mutations in three (8.8%) samples, and inactivating alterations in tumor suppressors TP53 , PTEN , RB1 , APC , CDKN1B , BRCA2 , and PIK3R1 .
|
29206995 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers.
|
28810879 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Speckle-type POZ protein (SPOP) is a member of the MATH-BTB protein family and is a type of joint molecule for Cullin-3.SPOP inhibits tumor growth.
|
28928843 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our data identify the tumor suppressor SPOP as an upstream negative regulator for HDAC6 stability, and SPOP loss-of-function mutations might lead to elevated levels of the HDAC6 oncoprotein to facilitate tumorigenesis and metastasis in various human cancers.
|
28599312 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, SPOP acts as a tumor suppressor by promoting senescence through degrading SENP7.
|
26527005 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time polymerase chain reaction analysis showed a lower level of SPOP expression in tumors carrying SPOP mutations than their matched normal prostate tissues.
|
24994784 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, SPOP expression was observed to negatively correlate with the tumor grade and intrahepatic metastasis of HCC patients.
|
26156804 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts.
|
26544944 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, decreased SPOP was associated disease progression in glioma samples, the expression level of SPOP was positively correlated with mean tumor diameter (MTD) (P=0.021) and the status of tumor grade and histological type (WHO I, II, III and IV) (P=0.032) in glioma patients.
|
25351530 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Altered expression and somatic mutations of SPOP have been observed in various tumor types with chromosomal aberrations, indicating a role of SPOP in maintaining genome stability, although a detailed mechanism remains unclear.
|
24451148 |
2014 |